Skip to main content
Publications
Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Beyhagh H, Toback S. Reactogenicity differences between adjuvanted, protein-based and messenger ribonucleic acid (mRNA)-based COVID-19 vaccines. Vaccines (Basel). 2024 Jul 19;12(7):802. doi: 10.3390/vaccines12070802
Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, Barrett AM, An D, Bishop KM, Youakim JM. Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. Med. 2024 Jul 17. doi: 10.1016/j.medj.2024.06.007
Connor MJ, Genie M, Dudderidge T, Wu H, Sukumar J, Beresford M, Bianchini D, Goh C, Horan G, Innominato P, Khoo V, Klimowska-Nassar N, Madaan S, Mangar S, McCracken S, Ostler P, Paisey S, Robinson A, Rai B, Sarwar N, Srihari N, Jayaprakash KT, Varughese M, Winkler M, Ahmed HU, Watson V, IP5-MATTER Trial Investigators. Patients' preferences for cytoreductive treatments in newly diagnosed metastatic prostate cancer: the IP5-MATTER study. Eur Urol Oncol. 2024 Jul 6;S2588-9311(24):00158-5. doi: 10.1016/j.euo.2024.06.010
Norman K, Bettger J, Dong C, French A, Lake A, Tchuisseu YP, Repka S, Vasudeva K, Whitaker R. Perspectives of telehealth and the impact on equity in access to health care from community members and healthcare providers: a multimethod analysis. Poster presented at the Academy Health 2024 Annual Research Meeting; June 30, 2024. Baltimore, MD.
Norman K, Barton K, Boucher H, Collyar D, Doemberg S, King H, Lydon E, Miller J, Oakes M, Radar A, Ruffin F, Skalla L, Wang T-W. A systematic review of patient-reported health-related quality of life measurement in patients with acute bacterial skin and skin structure infection. Poster presented at the Academy Health 2024 Annual Research Meeting; June 30, 2024. Baltimore, MD.
Paller AS, Siegfried EC, Marron SE, Clark M, Harris N, Kosa K, Qin S, Whalley D, Chao J, Bansal A, Chuang CC, Wang Z. Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis. J Eur Acad Dermatol Venereol. 2024 Jun 29. doi: 10.1111/jdv.20199
Taieb J, Fakih M, Salvatore L, Esaki T, Modest DP, Paez D, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Wang J, Tran Q, Chao J, Chen Z, Pietrantonio F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. Poster presented at the ESMO 2024 Gastrointestinal Cancers Annual Congress; June 26, 2024. Munich, Germany.
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438
Passamonti F, Parikh RC, Korgaonkar S, Chevli M, Yucel A, Rombi J, Zissler D, Davis KL, Slaff S. Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with myelofibrosis treated with fedratinib. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Campelo MD, Yucel A, Goyal RK, Glassberg MB, Esterberg L, Rombi J, Davis KL, Jimenez M, Miteva D, Germing U. Luspatercept utilization patterns in lower-risk myelodysplastic syndrome (LR-MDS): findings from a multinational medical record review study. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Schuh AC. Real-World treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Martin S, Kosa K, Podgrabinska S, Garg A, Oral EA, Yildirim Simsir I, Brown RJ, Ozen S, Pagovich O, Srinivasan D, Sanchez RJ. Qualitative interviews describing the patient experience of individuals with generalized lipodystrophy enrolled in a clinical trial of mibavademab. Poster presented at the Endocrine Society (ENDO) 2024; June 1, 2024. Boston, MA.
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554
